Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

Lenacapavir has shown high efficacy in managing multidrug-resistant cases, offering hope to patients with limited alternatives. A significant breakthrough in treating the Human Immunodeficiency ...

In a major step forward in the fight against HIV/AIDS, the US Food and Drug Administration (FDA) has approved Lenacapavir, an ...

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

A milestone was reached in the fight against HIV/AIDS with the development of Lenacapavir, a new injectable drug that ...

Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...